# Pazopanib

Source: https://onco.cc/drugs/pazopanib/  
OnCo record `pazopanib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.

## Summary

Pazopanib is an ATP-competitive inhibitor of VEGFR1-3, PDGFR alpha and beta, KIT and FGFR that starves tumours of new blood vessels. It is the only multi-kinase inhibitor approved for soft-tissue sarcoma and is used after chemotherapy fails. In PALETTE, patients with non-adipocytic soft-tissue sarcoma after anthracycline had PFS 4.6 versus 1.6 months on placebo (HR 0.31) but no OS benefit, and the FDA approved it in April 2012; liposarcoma was excluded after poor phase 2 results. It was first approved in 2009 for advanced renal cell carcinoma, where newer combinations have largely displaced it. Liver enzyme elevation carries a boxed warning, hypertension affected 41%, fatigue 65%, and pneumothorax in about 3% is a sarcoma-specific concern; Novartis markets it. Pazopanib delays progression in sarcoma without clearly extending life, a trade-off weighed against its side effects.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Votrient
- Modality: Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)
- Mechanism: ATP-competitive inhibitor of VEGFR1-3, PDGFRα/β, KIT, FGFR.
- Approvals: US 2009: Advanced renal cell carcinoma; US 2012: Advanced non-adipocytic soft-tissue sarcoma after chemotherapy
- Dosing: Oral; 800 mg once daily on an empty stomach
- Toxicity (grade 3+): Hypertension 7%; Fatigue 13%; ALT elevation 8%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Pazopanib
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pazopanib

## Connected records

- cancers: [Alveolar soft part sarcoma](https://onco.cc/cancers/alveolar-soft-part-sarcoma/), [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/), [Dermatofibrosarcoma protuberans](https://onco.cc/cancers/dermatofibrosarcoma-protuberans/), [Desmoplastic small round cell tumour](https://onco.cc/cancers/desmoplastic-small-round-cell-tumour/), [Epithelioid haemangioendothelioma](https://onco.cc/cancers/epithelioid-haemangioendothelioma/), [Leiomyosarcoma](https://onco.cc/cancers/leiomyosarcoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Retroperitoneal sarcoma](https://onco.cc/cancers/retroperitoneal-sarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/), [Synovial sarcoma](https://onco.cc/cancers/synovial-sarcoma/), [Undifferentiated pleomorphic sarcoma (UPS)](https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/), [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/), [Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)](https://onco.cc/cancers/vascular-tumours/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KIT](https://onco.cc/targets/kit/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- trials: [A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma](https://onco.cc/trials/nct07087158/), [Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma](https://onco.cc/trials/aldoxorubicin-phase-3-sts/), [Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)](https://onco.cc/trials/nct03260894/), [TAPPAS](https://onco.cc/trials/tappas/)
- pathways: [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/), [The angiogenic switch & tumour vessels](https://onco.cc/pathways/angiogenic-switch/)
- drugs: [Carotuximab](https://onco.cc/drugs/carotuximab/), [Cediranib](https://onco.cc/drugs/cediranib/)

---
JSON: https://onco.cc/api/v1/entities/pazopanib.json